drugset / Trial / NCT00997308

A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers

NCT00997308

Phase 1 Completed 97 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

This study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of two doses of AZD1446 or placebo in subjects when given for 4 weeks.

Timeline

Start
2009-10
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1446 Small molecule Oral

Indications

No indication recorded.